These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32886531)

  • 1. Advances in lyotropic liquid crystal systems for skin drug delivery.
    Silvestrini AVP; Caron AL; Viegas J; Praça FG; Bentley MVLB
    Expert Opin Drug Deliv; 2020 Dec; 17(12):1781-1805. PubMed ID: 32886531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals.
    Rajabalaya R; Musa MN; Kifli N; David SR
    Drug Des Devel Ther; 2017; 11():393-406. PubMed ID: 28243062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of biomacromolecules with reverse hexagonal liquid crystals: drug delivery and crystallization applications.
    Libster D; Aserin A; Garti N
    J Colloid Interface Sci; 2011 Apr; 356(2):375-86. PubMed ID: 21315366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Lamellar Lyotropic Liquid Crystalline Lipid Nanoparticles for the Next Generation of Nanomedicine.
    Zhai J; Fong C; Tran N; Drummond CJ
    ACS Nano; 2019 Jun; 13(6):6178-6206. PubMed ID: 31082192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic and Dynamic Heterogeneity of Nonlamellar Lyotropic Liquid Crystalline Nanodispersions.
    Yaghmur A; Moghimi SM
    ACS Nano; 2023 Nov; 17(22):22183-22195. PubMed ID: 37943319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lyotropic liquid crystalline phases: Drug delivery and biomedical applications.
    Chavda VP; Dyawanapelly S; Dawre S; Ferreira-Faria I; Bezbaruah R; Rani Gogoi N; Kolimi P; Dave DJ; Paiva-Santos AC; Vora LK
    Int J Pharm; 2023 Nov; 647():123546. PubMed ID: 37884213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembled nano-architecture liquid crystalline particles as a promising carrier for progesterone transdermal delivery.
    Elgindy NA; Mehanna MM; Mohyeldin SM
    Int J Pharm; 2016 Mar; 501(1-2):167-79. PubMed ID: 26828671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lyotropic liquid crystal-based transcutaneous peptide delivery system: Evaluation of skin permeability and potential for transcutaneous vaccination.
    Kozaka S; Wakabayashi R; Kamiya N; Goto M
    Acta Biomater; 2022 Jan; 138():273-284. PubMed ID: 34774785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanostructured liquid-crystalline particles for drug delivery.
    Lancelot A; Sierra T; Serrano JL
    Expert Opin Drug Deliv; 2014 Apr; 11(4):547-64. PubMed ID: 24490701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies.
    Vitoria Pupo Silvestrini A; Wender Debiasi B; Garcia Praça F; Vitoria Lopes Badra Bentley M
    Int J Pharm; 2022 Nov; 628():122299. PubMed ID: 36265664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topically applied lipid- and surfactant-based nanoparticles in the treatment of skin disorders.
    Desmet E; Van Gele M; Lambert J
    Expert Opin Drug Deliv; 2017 Jan; 14(1):109-122. PubMed ID: 27348356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling molecular transport and sustained drug release in lipid-based liquid crystalline mesophases.
    Zabara A; Mezzenga R
    J Control Release; 2014 Aug; 188():31-43. PubMed ID: 24910192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lyotropic liquid crystals for parenteral drug delivery.
    Chavda VP; Dawre S; Pandya A; Vora LK; Modh DH; Shah V; Dave DJ; Patravale V
    J Control Release; 2022 Sep; 349():533-549. PubMed ID: 35792188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and In Vitro Permeation Study of Cubic Liquid Crystal Containing Sinomenine Hydrochloride.
    Chu X; Li Q; Gui S; Li Z; Cao J; Jiang J
    AAPS PharmSciTech; 2018 Jul; 19(5):2237-2246. PubMed ID: 29740759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in versatile inverse lyotropic liquid crystals.
    Shan X; Luo L; Yu Z; You J
    J Control Release; 2022 Aug; 348():1-21. PubMed ID: 35636617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pluronic P123/DMSO Lyotropic Liquid Crystal for Incorporating Bioactive Substances for Topical Application.
    Selivanova NM; Galeeva AI; Ziganshin MA; Galyametdinov YG
    J Phys Chem B; 2024 May; 128(20):5127-5134. PubMed ID: 38736379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cubic and hexagonal liquid crystals as drug delivery systems.
    Chen Y; Ma P; Gui S
    Biomed Res Int; 2014; 2014():815981. PubMed ID: 24995330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lyotropic liquid crystal systems in drug delivery.
    Guo C; Wang J; Cao F; Lee RJ; Zhai G
    Drug Discov Today; 2010 Dec; 15(23-24):1032-40. PubMed ID: 20934534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach.
    Waghule T; Dabholkar N; Gorantla S; Rapalli VK; Saha RN; Singhvi G
    Biomed Pharmacother; 2021 Sep; 141():111940. PubMed ID: 34328089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid crystalline nanoreservoir releasing a highly skin-penetrating berberine oleate complex for psoriasis management.
    Freag MS; Torky AS; Nasra MM; Abdelmonsif DA; Abdallah OY
    Nanomedicine (Lond); 2019 Apr; 14(8):931-954. PubMed ID: 30925102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.